[NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

This study includes genetic testing of your tumor sample and chemotherapy. The purpose of the genetic testing is to see if your tumor has features that certain study drugs used in this trial are designed to work against. After the genetic testing and additional tests, you will receive a study drug and/or a drug that is part of the usual treatment for your type of cancer. This study will help the investigators know whether taking the study drug is the better, the same, or worse than the usual treatment. It will also help the investigators know if genetic testing can identify participants who will or will not benefit from treatment.

Medical Condition(s)

Squamous cell non-small cell lung cancer

Eligibility Criteria

1. Advanced (stage IIIB or stage IV) squamous cell non-small cell lung cancer
2. Participants must have received one regimen of chemotherapy. The chemotherapy must have included a platinum containing drug.
3. At least 18 years old
4. If your tumor has already been genetically tested, a known mutation in your EGFR gene or an ALK gene fusion makes you ineligible for the study.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

Participants will have clinic visits and take study drug until their can

Minors Included



Knight Information Line - or 503-494-1080



Recruitment End


Compensation Provided



If patients consent to the optional S1400GEN study during the screening/pre-screening consent they will be compensated with a one time $20 amazon gift card. The gift card will be is distributed by Fred Hutchinson Cancer Center.

Go Back